News & Articles

The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people...

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its...

When: January 11, 2016 – January 14, 2016 (all-day) Where: San Francisco, CA, USA Calendar: Healthcare Investor Conferences ...

Stop by at SFN to see Impel’s Device in Poster Presentations Be sure to check out these poster presentations featuring the POD devices at SFN 2015 in Chicago this week! Monday, October 19, 2015 1:00 pm – 5:00 pm McCormick Place Hall A | Program#/Poster#: 395.18/D39 L Tan, Ph.D., Salk Institute Intranasal administration of a small molecule...

SEATTLE, Wash., October 30, 2014 – Impel NeuroPharma is pleased toannounce that H. Stewart Parker, a prominent leader in Seattle’s Biotechnology community, has joined Impel’s Board of Directors. Most recently, Parker was the CEO of the Seattle-based Infectious Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines,...

March 24, 2014 – A nasal spray that delivers a new type of depression treatment holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows. The study, led by CAMH’s Dr. Fang Liu, is published online in Neuropsychopharmacology. In a previous study published in...